LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Multicentric reticulohistiocytosis associated with organizing pneumonia.

    Nguyen, Yann / Huynh, Sandra / de Clippele, Donatienne / Vignon-Pennamen, Marie-Dominique / Petit, Antoine / Frumholtz, Laure

    Joint bone spine

    2021  Volume 88, Issue 5, Page(s) 105192

    MeSH term(s) Arthritis ; Histiocytosis, Non-Langerhans-Cell/complications ; Histiocytosis, Non-Langerhans-Cell/diagnosis ; Histiocytosis, Non-Langerhans-Cell/drug therapy ; Humans ; Pneumonia
    Language English
    Publishing date 2021-04-20
    Publishing country France
    Document type Letter
    ZDB-ID 2020487-5
    ISSN 1778-7254 ; 1297-319X
    ISSN (online) 1778-7254
    ISSN 1297-319X
    DOI 10.1016/j.jbspin.2021.105192
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4590: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.

    Huynh, Sandra / Lheure, Coralie / Franck, Nathalie / Goldman-Lévy, Gabrielle / Aractingi, Selim / Dupin, Nicolas / Kramkimel, Nora / Guégan, Sarah

    Melanoma research

    2020  Volume 30, Issue 3, Page(s) 317–320

    Abstract: Combined BRAF and MEK inhibition is one of the first-line treatment strategies for patients with advanced BRAF-mutant melanoma. Sarcoid-like reactions (SLRs) have occasionally been described with melanoma systemic treatments such as immunotherapy or the ... ...

    Abstract Combined BRAF and MEK inhibition is one of the first-line treatment strategies for patients with advanced BRAF-mutant melanoma. Sarcoid-like reactions (SLRs) have occasionally been described with melanoma systemic treatments such as immunotherapy or the BRAF inhibitor vemurafenib, but very few cases have been reported with dabrafenib and trametinib. Our aim was to better characterize SLR induced by this combination. We conducted a monocentric retrospective observational study among patients treated with dabrafenib and trametinib for BRAF-mutant advanced melanoma from January 2015 to March 2019. Patients presenting with histologically proven SLR were included. We also searched Medline database for all reported cases of SLR induced by targeted therapy. Of 63 patients on dabrafenib/trametinib combination, seven were diagnosed with a SLR. They all had specific cutaneous involvement, and one also displayed mediastinal and salivary glands involvement. None required systemic corticosteroids or dabrafenib/trametinib discontinuation. Three of them (43%) reached melanoma complete remission and are still on targeted therapy; and four patients progressed and died. A literature review yielded 22 additional cases of SLR induced by targeted therapy: the main affected organ was the skin, 11 patients (50%) had systemic involvement, five patients (23%) required systemic corticosteroids to reach partial or complete remission of SLR, 12 (55%) reached partial or complete response of melanoma while six (27%) progressed. BRAF and MEK inhibitors are potential triggers of SLR, although pathological mechanisms remain unclear. The mainstay of treatment is systemic or topical corticotherapy; targeted therapy discontinuation is usually not necessary.
    MeSH term(s) Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Humans ; Imidazoles/administration & dosage ; Imidazoles/adverse effects ; Male ; Melanoma/drug therapy ; Middle Aged ; Oximes/administration & dosage ; Oximes/adverse effects ; Pyridones/administration & dosage ; Pyridones/adverse effects ; Pyrimidinones/administration & dosage ; Pyrimidinones/adverse effects ; Retrospective Studies ; Sarcoidosis/chemically induced ; Skin Neoplasms/drug therapy ; Melanoma, Cutaneous Malignant
    Chemical Substances Imidazoles ; Oximes ; Pyridones ; Pyrimidinones ; trametinib (33E86K87QN) ; dabrafenib (QGP4HA4G1B)
    Language English
    Publishing date 2020-02-12
    Publishing country England
    Document type Journal Article ; Observational Study
    ZDB-ID 1095779-0
    ISSN 1473-5636 ; 0960-8931
    ISSN (online) 1473-5636
    ISSN 0960-8931
    DOI 10.1097/CMR.0000000000000649
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3378: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Congenital yellow nail syndrome presenting with eyelid lymphedema and fetal hydrops.

    El Alami, Jihane / Galicier, Lionel / Huynh, Sandra / Frumholtz, Laure / Bagot, Martine / de Masson, Adèle / Vignes, Stéphane / Bouaziz, Jean-David

    JAAD case reports

    2019  Volume 5, Issue 11, Page(s) 1010–1012

    Language English
    Publishing date 2019-11-06
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2834220-3
    ISSN 2352-5126
    ISSN 2352-5126
    DOI 10.1016/j.jdcr.2019.09.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Avulsion injury to the profunda femoris artery after total hip arthroplasty.

    Huynh, Sandra / Kayssi, Ahmed / Koo, Kevin / Rajan, Dheeraj / Safir, Oleg / Forbes, Thomas L

    Journal of vascular surgery

    2016  Volume 64, Issue 2, Page(s) 494–496

    Abstract: Vascular injuries are a rare complication of total hip arthroplasty (THA). We describe the case of 71-year-old man who underwent an elective left THA and developed a pseudoaneurysm from an avulsion injury to the first branch of the profunda femoris ... ...

    Abstract Vascular injuries are a rare complication of total hip arthroplasty (THA). We describe the case of 71-year-old man who underwent an elective left THA and developed a pseudoaneurysm from an avulsion injury to the first branch of the profunda femoris artery. The patient underwent urgent open primary repair of the pseudoaneurysm and recovered without any complications. This case demonstrates the importance of assessing for vascular injuries after THA and of educating patients about the associated signs and symptoms.
    MeSH term(s) Aged ; Aneurysm, False/diagnostic imaging ; Aneurysm, False/etiology ; Aneurysm, False/surgery ; Arthroplasty, Replacement, Hip/adverse effects ; Computed Tomography Angiography ; Elective Surgical Procedures ; Femoral Artery/diagnostic imaging ; Femoral Artery/injuries ; Femoral Artery/surgery ; Humans ; Male ; Treatment Outcome ; Vascular System Injuries/diagnostic imaging ; Vascular System Injuries/etiology ; Vascular System Injuries/surgery
    Language English
    Publishing date 2016-08
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 605700-7
    ISSN 1097-6809 ; 0741-5214
    ISSN (online) 1097-6809
    ISSN 0741-5214
    DOI 10.1016/j.jvs.2015.08.088
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1933: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study.

    Huynh, Sandra / Mortier, Laurent / Dutriaux, Caroline / Maubec, Eve / Boileau, Marie / Dereure, Olivier / Leccia, Marie-Therese / Arnault, Jean-Philippe / Brunet-Possenti, Florence / Aubin, Francois / Dreno, Brigitte / Beylot-Barry, Marie / Lebbe, Celeste / Lefevre, Wendy / Delyon, Julie

    Cancers

    2020  Volume 12, Issue 6

    Abstract: Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess the ... ...

    Abstract Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess the safety of combined ICI and TT as a rescue line in real-life clinical practice. We conducted a study within the prospective French multicentric MelBase cohort, including patients treated with a combination of anti-PD1 (pembrolizumab/nivolumab) and BRAF inhibitor (BRAFi: dabrafenib/vemurafenib) and/or MEK inhibitors (MEKi: trametinib/cobimetinib) for BRAF mutated or wild-type advanced melanoma. Fifty-nine patients were included: 30% received the triple combination, 34% an anti-PD1 and BRAFi, and 36% an anti-PD1 and MEKi. Grade 3-4 adverse events occurred in 12% of patients. Permanent discontinuation or dose reduction of one of the treatments for toxicity was reported in 14% and 7% of patients, respectively. In the BRAF wild-type subgroup, treatment with MEKi and anti-PD1 induced a tumor control rate of 83% and median progression-free survival of 7.1 months. The combination of anti-PD1 and BRAFi and/or MEKi was a safe rescue line for advanced melanoma patients previously treated with ICI/TT. The benefit of these combinations, specifically anti-PD1 and MEKi in BRAF wild-type melanoma patients, needs to be prospectively studied.
    Language English
    Publishing date 2020-06-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers12061666
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top